Figure 1.
Methylation of the TFPI-2 gene in bladder cancer is decreased by EGCG. Methylation-specific polymerase chain reaction analysis revealed (A) a significantly higher methylation level of TFPI-2 in bladder cancer compared with normal bladder tissue, and (B) significantly decreased methylation of TFPI-2 in T24 bladder cancer cells treated with EGCG. **P<0.01, ****P<0.0001. TFPI-2, tissue factor pathway inhibitor 2; EGCG, epigallocatechin gallate.